---
title: "Taltz (ixekizumab) in plaque psoriasis: Dosing and administration questions"
description: "Dosing and administration questions on Taltz (ixekizumab) in plaque psoriasis, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Administration, and Preparation. Questions: What is the Taltz dose for adult plaque psoriasis? What is the Taltz dose for children with plaque psoriasis? Can patients self-inject Taltz? How many patients found the Taltz autoinjector easy to use? 1 further question follow. 5 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T16:49:54-05:00"
---

# Taltz (ixekizumab) in plaque psoriasis: Dosing and administration questions

Manufacturer: Eli Lilly and Company  
Prescribing information: [Taltz](https://uspl.lilly.com/taltz/taltz.html#pi)

Dosing and administration questions that apply to every indication of Taltz are on [Taltz (ixekizumab), all indications: Dosing and administration](https://www.evicenter.com/medical-information/taltz/dosing-and-administration).

## Dosing

<a id="taltz-adult-dose"></a>

### What is the Taltz dose for adult plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “The recommended dosage in adults with moderate-to-severe plaque psoriasis is 160 mg (two 80 mg injections) at Week 0, followed by 80 mg at Weeks 2, 4, 6, 8, 10, and 12, then 80 mg every 4 weeks.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=The%20recommended%20dosage%20in%20adults,80%20mg%20every%204%20weeks.)

> “The Taltz dosing regimen starts with one starter dose of two 80 milligram injections on the same day. During the induction period, the dose is one injection of 80 milligrams every two weeks from Week 2 through Week 12. During the maintenance period starting Week 16, the dose is one injection of 80 milligrams every four weeks thereafter.”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=The%20Taltz%20dosing%20regimen%20starts,milligrams%20every%20four%20weeks%20thereafter.)

<a id="taltz-pediatric-dose"></a>

### What is the Taltz dose for children with plaque psoriasis?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “TALTZ is administered by subcutaneous injection every 4 weeks (Q4W). The recommended dosage in pediatric patients from 6 to less than 18 years of age with moderate-to-severe plaque psoriasis is based on the following weight categories.
>
> Table 1: Recommended Dosage for Pediatric Patients 6 Years of Age and Older with Plaque Psoriasis
> Pediatric Patient's Weight	Starting Dose (Week 0)	Dose every 4 weeks (Q4W) Thereafter
> Greater than 50 kg	160 mg (two 80 mg injections)	80 mg
> 25 to 50 kg	80 mg	40 mg
> Less than 25 kg	40 mg	20 mg”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%20is%20administered%20by%20subcutaneous%20injection%20every,20%20mg)

## Administration

<a id="taltz-self-injection"></a>

### Can patients self-inject Taltz?

> “TALTZ is intended for use under the guidance and supervision of a healthcare provider. Adult patients may self-inject or caregivers may give injections of TALTZ after training in subcutaneous injection technique using the autoinjector or prefilled syringe. Safety and effectiveness of pediatric self-administration has not been established. Therefore, TALTZ should be administered to pediatric patients by a healthcare provider or by a caregiver who has received training and demonstrated proper subcutaneous injection technique.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%20is%20intended%20for%20use,demonstrated%20proper%20subcutaneous%20injection%20technique.)

> “TALTZ 20 mg and 40 mg doses prepared from the TALTZ 80 mg/mL prefilled syringe should only be administered by a qualified healthcare professional [see Dosage and Administration (2.8)].”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=TALTZ%2020%20mg%20and%2040,%5Bsee%20Dosage%20and%20Administration%20%282.8%29%5D.)

<a id="taltz-autoinjector-ease"></a>

### How many patients found the Taltz autoinjector easy to use?

Applies to: Moderate-to-severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy

> “At first use, over 94% of adult patients with moderate to severe plaque psoriasis agreed the Taltz autoinjector was "easy to use" and were confident in their ability to use it.”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=At%20first%20use%2C%20over%2094%25,their%20ability%20to%20use%20it.)

> “Callis Duffin K, Bukhalo M, Bobonich MA, et al. Usability of a novel disposable autoinjector device for ixekizumab: results from a qualitative study and an open-label clinical trial, including patient-reported experience. Med Devices (Auckl). 2016;9:361-369.”

Source: [TALTZ: Plaque Psoriasis (PsO) Dosing Schedule & Devices, captured 2026-11-14](https://taltz.lilly.com/hcp/dermatology/dosing-schedule#:~:text=Callis%20Duffin%20K%2C%20Bukhalo%20M%2C,experience.%20Med%20Devices%20%28Auckl%29.%202016%3B9%3A361%2D369.)

Note: The device study design is behind a "Device trial design" link on the Taltz HCP dosing page; its text was not part of the capture. The last passage is an entry of the dosing page's reference list, a 2016 usability study of the Taltz autoinjector.

## Preparation

<a id="taltz-pediatric-dose-preparation"></a>

### How are 20 mg and 40 mg Taltz doses prepared for children?

Applies to: Moderate-to-severe plaque psoriasis in pediatric patients 6 to less than 18 years of age

> “If the 20 mg/0.25 mL or 40 mg/0.5 mL prefilled syringe is unavailable, TALTZ doses of 20 mg or 40 mg for pediatric patients with plaque psoriasis [see Dosage and Administration (2.3)] must be manually prepared according to the steps below using only the TALTZ 80 mg/mL prefilled syringe. The preparation and administration of the 20 mg and 40 mg doses should only be performed by a qualified healthcare professional. For additional preparation and administration instructions, [see Dosage and Administration (2.7)].
>
> Gather the following necessary supplies for preparation:
> 0.5 mL or 1 mL disposable syringe
> Sterile needle for withdrawal
> 27-gauge sterile needle for administration
> Sterile, clear glass vial.
> Expel the entire contents of the prefilled syringe into the sterile vial. DO NOT shake or swirl the vial. Do not add other medications to solutions containing TALTZ.
> Using the 0.5 mL or 1 mL disposable syringe and sterile needle, withdraw the prescribed dose from the vial (0.25 mL for 20 mg; 0.5 mL for 40 mg).
> Remove the needle from the syringe and replace it with a 27-gauge needle prior to administering TALTZ.
>
> Storage of Prepared TALTZ
>
> If necessary, TALTZ 20 mg or 40 mg doses prepared from an 80 mg/mL prefilled syringe may be stored at room temperature for up to 4 hours from first puncturing the sterile vial.”

Source: [TALTZ: Prescribing information, captured 2026-11-14](https://uspl.lilly.com/taltz/taltz.html#pi:~:text=If%20the%2020%20mg%2F0.25%20mL,first%20puncturing%20the%20sterile%20vial.)

## Related pages
- [Medical information: Taltz (ixekizumab): Plaque psoriasis](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis)
- [Indication](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/safety)
- [Specific populations](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/drug-interactions)
- [Guidelines](https://www.evicenter.com/medical-information/taltz--plaque-psoriasis/guidelines)
